ArticleJournal of personalized medicine2021
Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types.
Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Unraveling Cardiovascular Risks and Benefits of COVID-19 Vaccines: A Systematic Review.Cardiovascular toxicology · 2025Pooled it
- COVID-19 vaccine induced myocarditis in young males: A systematic review.European journal of clinical investigation · 2023Pooled it
- Myocarditis after COVID-19 mRNA vaccination: A systematic review of case reports and case series.Clinical cardiology · 2022Pooled it
- Pooled it
- Is Covid-19 "vaccine uptake" in postsecondary education a "problem"? A critical policy inquiry.Health (London, England : 1997) · 2024Article
- Article
- COVID-19 Vaccines in Children.Journal of clinical medicine · 2023Review
- Common pathological findings in the heart in COVID-19-related sudden death cases: An autopsy case series.Heliyon · 2023Article
- Dermatomyositis Flare-Up Following the SARS-CoV-2 Vaccine: A Case Report and Literature Review.Cureus · 2023Article
- Myocarditis and Pericarditis Post-mRNA COVID-19 Vaccination: Insights from a Pharmacovigilance Perspective.Journal of clinical medicine · 2023Article
- Review
- COVID-19 Vaccines and Myocarditis: An Overview of Current Evidence.Biomedicines · 2023Review
- Predictors of persistent symptoms after mRNA SARS-CoV-2 vaccine-related myocarditis (myovacc registry).Frontiers in cardiovascular medicine · 2023Article
- Appraising the decision-making process concerning COVID-19 policy in postsecondary education in Canada: A critical scoping review protocol.AIMS public health · 2023Article
- Myocarditis following Coronavirus vaccination.Clinical immunology communications · 2022Article
- Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines.Journal of the American College of Cardiology · 2022Article
- Acute myocarditis after COVID-19 vaccination.Saudi medical journal · 2022Article
- Correspondence on 'BNT162b2 vaccine-associated myo/pericarditis in adolescents'.European journal of clinical investigation · 2022Article
- COVID-19 Vaccines and Myopericarditis: A Nuanced Story.Journal of personalized medicine · 2022Article
- Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.BMJ (Clinical research ed.) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing number of myocarditis/pericarditis incidences has been reported after coronavirus disease-19 (COVID-19) vaccination in adolescents and young adults. This study was designed to investigate the incidence rate of-and risk for-myocarditis and pericarditis following COVID-19 vaccination in the United States according to age and vaccine type. This study used the Vaccine Adverse Events Reporting System (VAERS) from 11 December 2020 to 13 August 2021. A population-based data mining approach was performed based on the reporting odds ratio (ROR). Adverse events of myocarditis and pericarditis following COVID-19 vaccination were rare, with an incidence rate of 5.98 (95% CI = 5.73-6.24) cases per million doses administered. The incidence rate was higher in adolescents and after the administration of the second dose of messenger RNA (mRNA) vaccines. Overall, two mRNA vaccines were significantly associated with increased risks for myocarditis/pericarditis (mRNA-1273 (Moderna): ROR = 2.91, 95% CI = 2.21-3.83; BNT162b2 (Pfizer-BioNTech): ROR = 5.37, 95% CI = 4.10-7.04) compared to all other vaccines from VAERS. The viral vector vaccine of Ad26.COV2.S (Janssen) was not associated with signals of myocarditis/pericarditis (ROR = 1.39; 95% CI = 0.99-1.97). This study found increased risks for myocarditis/pericarditis following mRNA COVID-19 vaccines. For patients at high risk for myocarditis/pericarditis or with myocardial injuries, the viral vector vaccine may be an alternative for consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.